摘要
目的观察奥沙利铂（L—OHP）联合卡培他滨治疗晚期大肠癌的疗效和毒副反应。方法35例均为有可测量病灶的晚期大肠癌患者，静脉注射L—OHP130mg／m^2，第1天；卡培他滨2500mg／m^2，分早晚2次cr服，连用14d，每3周为1周期，每位患者至少接受2个周期化疗。结果35例患者中完全缓解（CR）2例（5．7％），部分缓解（PR）11例（31．4％），稳定（SD）14例（40．0％）；进展（PD）9例（25．7％），总有效RR（CR＋PR）13例（37．1％），中位生存期（MST）12．3个月，中位疾病进展时间（TTP）7．8个月。该方案主要毒性反应为神经毒性、手足综合征，周围神经毒性多为Ⅰ～Ⅱ度。结论该方案具有较好的疗效，毒副作用少，易耐受，提高生活质量。
Objective To observe the clinical effect and toxicity of oxalipclatin plus capecitabine for the treatment of advanced colorectal cancer. Methods Thirty-five patients with advanced eolorectal cancer having measurable lesions were treated with L-OHP（ 130 mg/m^2 ivgtt, the first day） combined with eapeeitabine （2500 mg/m2, P.O. from the first day to the 14th day, twice a day）, 3 weeks as a cycle. The treatment was finished 2 recycles at least. Results Among the 35 patients, the overall response rate（CR ＋ PR）was 37.1%,with 2 cases（5.7%） CR, 11 cases（31.4%） PR, 14 cases （40.0%） SD, 9 cases（25.7% ） PD, MTS was 12.3 months, Mttp was 7.8 months. The main toxicity reactions were hand-foot syndrome and neurosensory toxicity（ grade Ⅰ～Ⅱ ）. Conclusions Oxalipclatin combined with capecitabine is effective in the treatment of advanced colorectal cancer, with less toxicity reactions, is tolerable and can improve quality of life.
出处
《中国实用医刊》
2012年第4期34-35,共2页
Chinese Journal of Practical Medicine
关键词
晚期大肠癌
奥沙利铂
卡培他滨
化疗
Advanced colorectal cancer
Oxalipclatin
Capecitabine
Chemotherapy
